APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28087008.
- Also identified by DOI 10.1016/j.kint.2016.10.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several landmark trials have assessed the effects of aggressive hypertension control on the progression of nondiabetic chronic kidney disease. Results generally have been disappointing. With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease. This commentary reviews the current findings and extends the discussion to apolipoprotein L1 gene by blood pressure (or gene by environment) interactions.
Medical subject headings
- Apolipoproteins
- Blood Pressure